Advanced search
Publication Cover
Infectious Diseases Volume 56, 2024 - Issue 7
Submit an article Journal homepage
964
Views
0
CrossRef citations to date
0
Altmetric
Brief Report

Outcomes and clinical characteristics of the compassionate use of plitidepsin in COVID-19 patients with solid tumours, haematological malignancies or anti-CD20 antibody treatment

Jose Aguarelesa Internal Medicine Department, Hospital Universitario Quirónsalud Madrid, Madrid, Spain;b Facultad de Ciencias Biomédicas y de la Salud, Medicine Department, Universidad Europea de Madrid, Madrid, Spain;c Research and Clinical Trials Unit, Hospital Universitario Quirónsalud Madrid, Madrid, SpainView further author information
,
Paula Villares Fernándezd Internal Medicine Department, Hospital Universitario HM Sanchinarro, Madrid, SpainView further author information
,
Carles Fornée Heorfy Consulting, Lleida, Spain;f Basic Medical Sciences Department, University of Lleida, Lleida, SpainView further author information
,
Eva María Martí-Ballesterosb Facultad de Ciencias Biomédicas y de la Salud, Medicine Department, Universidad Europea de Madrid, Madrid, Spain;g Haematology Department, Hospital Universitario Quirónsalud Madrid, Madrid, SpainView further author information
,
Virginia Pradillo Fernándezb Facultad de Ciencias Biomédicas y de la Salud, Medicine Department, Universidad Europea de Madrid, Madrid, Spain;g Haematology Department, Hospital Universitario Quirónsalud Madrid, Madrid, SpainView further author information
,
Gabriel Sotres-Fernandeza Internal Medicine Department, Hospital Universitario Quirónsalud Madrid, Madrid, Spain;b Facultad de Ciencias Biomédicas y de la Salud, Medicine Department, Universidad Europea de Madrid, Madrid, SpainView further author information
,
Adolfo de la Fuente-Burguerah Haematology and Haemotherapy Service, MD Anderson Cancer Center, Madrid, SpainView further author information
,
Carolina Navarro-San Franciscoi Infectious Diseases Unit, Internal Medicine Department, Hospital Universitario de Burgos, Burgos, SpainView further author information
,
Luis Miguel Buzón-Martíni Infectious Diseases Unit, Internal Medicine Department, Hospital Universitario de Burgos, Burgos, SpainView further author information
,
Teresa García-Delanguej Internal Medicine Department, Hospital HLA Universitario Moncloa, Madrid, SpainView further author information
,
Francesco Tommaso Aiellok Internal Medicine Department, Hospital Clinic de Barcelona, Barcelona, SpainView further author information
,
Daniel Carnevali-Ruiza Internal Medicine Department, Hospital Universitario Quirónsalud Madrid, Madrid, Spain;b Facultad de Ciencias Biomédicas y de la Salud, Medicine Department, Universidad Europea de Madrid, Madrid, SpainView further author information
,
Raquel Llorisl VirologyUnit, PharmaMar S.A., Madrid, SpainView further author information
,
Xavier Erik Luepke-Estefanm Coordinator of Compassionate Drug Use, PharmaMar S.A., Madrid, SpainView further author information
,
José Antonio López-Martínl VirologyUnit, PharmaMar S.A., Madrid, SpainView further author information
,
José María Jimenol VirologyUnit, PharmaMar S.A., Madrid, SpainView further author information
,
Ana García-Casasa Internal Medicine Department, Hospital Universitario Quirónsalud Madrid, Madrid, Spain;c Research and Clinical Trials Unit, Hospital Universitario Quirónsalud Madrid, Madrid, SpainView further author information
&
Pablo Guisado-Vascoa Internal Medicine Department, Hospital Universitario Quirónsalud Madrid, Madrid, Spain;b Facultad de Ciencias Biomédicas y de la Salud, Medicine Department, Universidad Europea de Madrid, Madrid, SpainCorrespondence[email protected]
View further author information
 show all
Pages 575-580 | Received 25 Jan 2024, Accepted 30 Apr 2024, Published online: 14 May 2024

References

  • Tan WC, Tan JYJ, Lim JSJ, et al. COVID-19 severity and waning immunity after up to 4 mRNA vaccine doses in 73 608 patients with cancer and 621 475 matched controls in Singapore: a nationwide cohort study. JAMA Oncol. 2023;9(9):1221–1229. doi: 10.1001/jamaoncol.2023.2271.
  • Potter AL, Vaddaraju V, Venkateswaran S, et al. Deaths due to COVID-19 in patients with cancer during different waves of the pandemic in the US. JAMA Oncol. 2023;9(10):1417–1422. doi: 10.1001/jamaoncol.2023.3066.
  • Ofer J, Drozdinsky G, Basharim B, et al. Mortality and hospitalization risks in patients with cancer and the SARS-CoV-2 omicron variant. JAMA Oncol. 2023;10(1):e235042–e235138. doi: 10.1001/jamaoncol.2023.5042.
  • Lee CY, Shah MK, Hoyos D, et al. Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies. Cancer Discov. 2022;12(1):62–73. doi: 10.1158/2159-8290.CD-21-1033.
  • Meyerowitz EA, Li Y. Review: the landscape of antiviral therapy for COVID-19 in the era of widespread population immunity and Omicron-Lineage viruses. Clin Infect Dis. 2023;78:908–917.
  • Aguareles J, Fernández PV, Carralón-González MM, et al. Outcomes and clinical characteristics of the compassionate use of plitidepsin for immunocompromised adult patients with COVID-19. Int J Infect Dis. 2023;135:12–17.
  • Varona JF, Landete P, Lopez-Martin JA, et al. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19. Life Sci Alliance. 2022;5(4):e202101200. doi: 10.26508/lsa.202101200.
  • Kang S-W, Kim J-W, Kim JY, et al. Virological characteristics and the rapid antigen test as deisolation criteria in immunocompromised patients with COVID-19: a prospective cohort study. J Med Virol. 2023;95(11):e29228.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.